Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Jia, Danlin ^a   Rahbar, Ramtin ^a   Chan, Renee W Y ^b   Lee, Suki M Y ^b   Chan, Michael C W ^b   Wang, Ben Xuhao ^a   Baker, Darren P ^c   Sun, Bing ^d   Malik Peiris, J S ^b   Nicholls, John M ^b   Fish, Eleanor N ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c BIOGEN   (United States)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; ALPHA INTERFERON RECEPTOR 2; CONSENSUS INTERFERON; INTERFERON; NONSTRUCTURAL PROTEIN 1; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; GREEN FLUORESCENT PROTEIN; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; INS1 PROTEIN, INFLUENZA VIRUS; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; DNA PROTEIN COMPLEX; EX VIVO STUDY; GENE EXPRESSION REGULATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INHIBITION KINETICS; LUNG PARENCHYMA; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INHIBITION; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOBLOTTING; INFLUENZA VIRUS A; LUNG; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CULTURE TECHNIQUE; VIROLOGY;

AVES; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

CELLS, CULTURED; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOBLOTTING; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INTERFERONS; LUNG; MACROPHAGES; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; RECEPTOR, INTERFERON ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TISSUE CULTURE TECHNIQUES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 78649732404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013927     Document Type: Article

References (66)

1. Saito T, Gale M, Jr. (2007) Principles of intracellular viral recognition. Curr Opin Immunol 19: 17-23.
2. Bonjardim CA, Ferreira PC, Kroon EG (2009) Interferons: signaling, antiviral and viral evasion. Immunol Lett 122: 1-11.
3. Hengel H, Koszinowski UH, Conzelmann KK (2005) Viruses know it all: new insights into IFN networks. Trends Immunol 26: 396-401.
4. Hale BG, Randall RE, Ortin J, Jackson D (2008) The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89: 2359-2376.
5. Guo Z, Chen LM, Zeng H, Gomez JA, Plowden J, et al. (2007) NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol 36: 263-269.
6. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 59-phosphates. Science 314: 997-1001.
7. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M, Jr., et al. (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81: 514-524.
8. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, et al. (2009) Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5: 439-449.
9. Wang X, Li M, Zheng H, Muster T, Palese P, et al. (2000) Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 74: 11566-11573.
10. Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, et al. (2004) The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol 78: 11574-11582.
11. Qiu Y, Nemeroff M, Krug RM (1995) The influenza virus NS1 protein binds to a specific region in human U6 snRNA and inhibits U6-U2 and U6-U4 snRNA interactions during splicing. RNA 1: 304-316.
12. Shin YK, Li Y, Liu Q, Anderson DH, Babiuk LA, et al. (2007) SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J Virol 81: 12730-12739.
13. Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, et al. (2007) Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 81: 3058-3067.
14. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
15. Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC (2009) Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem Biophys Res Commun.
16. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, et al. (2009) Oseltamivir-and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 15: 966-968.
17. Lee SM, Cheung CY, Nicholls JM, Hui KP, Leung CY, et al. (2008) Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 198: 525-535.
18. Karber G (1931) 50% end-point calculation. Arch Exp Pathol Pharmak. pp 480-483.
19. Goldman LA, Zafari M, Cutrone EC, Dang A, Brickelmeier M, et al. (1999) Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res 19: 15-26.
20. Brierley MM, Marchington KL, Jurisica I, Fish EN (2006) Identification of GAS-dependent interferon-sensitive target genes whose transcription is STAT2-dependent but ISGF3-independent. FEBS J 273: 1569-1581.
21. Rahbar R, Murooka TT, Hinek AA, Galligan CL, Sassano A, et al. (2006) Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol 80: 7245-7259.
22. Van Hoeven N, Belser JA, Szretter KJ, Zeng H, Staeheli P, et al. (2009) Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol 83: 2851-2861.
23. Precious B, Young DF, Andrejeva L, Goodbourn S, Randall RE (2005) In vitro and in vivo specificity of ubiquitination and degradation of STAT1 and STAT2 by the V proteins of the paramyxoviruses simian virus 5 and human parainfluenza virus type 2. J Gen Virol 86: 151-158.
24. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, et al. (2006) Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 80: 9226-9235.
25. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, et al. (2003) Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 33: 388-391.
26. Park C, Li S, Cha E, Schindler C (2000) Immune response in Stat2 knockout mice. Immunity 13: 795-804.
27. Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
28. Zurney J, Howard KE, Sherry B (2007) Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol 81: 13668-13680.
29. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, et al. (1995) A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 92: 11284- 11288.
30. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, et al. (2009) Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49: 1847-1858.
31. Tena-Tomas C, Pedroso ML, de Messias-Reason IJ, Kremsner PG, Kun JF (2007) Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy. Eur Cytokine Netw 18: 136-141.
32. Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, et al. (2006) Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 60: 569-577.
33. Aucan C, Walley AJ, Hennig BJ, Fitness J, Frodsham A, et al. (2003) Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun 4: 275-282.
34. Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, et al. (2005) IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 163: 165-171.
35. Mowshowitz SL, Dawson GJ, Elizan TS (1983) Antiviral response of fibroblasts from familial Alzheimer's disease and Down's syndrome to human interferon-alpha. J Neural Transm 57: 121-126.
36. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM (1998) Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 39end formation of cellular pre-mRNAs. Mol Cell 1: 991-1000.
37. Chen Z, Li Y, Krug RM (1999) Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 39-end processing machinery. EMBO J 18: 2273-2283.
38. Fuke H, Ohno M (2008) Role of poly (A) tail as an identity element for mRNA nuclear export. Nucleic Acids Res 36: 1037-1049.
39. Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, et al. (2006) Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 80: 6295-6304.
40. Wang W, Riedel K, Lynch P, Chien CY, Montelione GT, et al. (1999) RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 5: 195-205.
41. Bornholdt ZA, Prasad BV (2008) X-ray structure of NS1 from a highly pathogenic H5N1 influenza virus. Nature 456: 985-988.
42. Pauli EK, Schmolke M, Wolff T, Viemann D, Roth J, et al. (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog 4: e1000196.
43. Pothlichet J, Chignard M, Si-Tahar M (2008) Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J Immunol 180: 2034-2038.
44. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, et al. (1999) Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19: 6396-6407.
45. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, et al. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320.
46. Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, et al. (2004) SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 320: 1007-1014.
47. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA (2009) Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol 22: 147-161.
48. Frey KG, Ahmed CM, Dabelic R, Jager LD, Noon-Song EN, et al. (2009) HSV-1-Induced SOCS-1 Expression in Keratinocytes: Use of a SOCS-1 Antagonist to Block a Novel Mechanism of Viral Immune Evasion. J Immunol.
49. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, et al. (2003) IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17: 488-490.
50. Krebs DL, Hilton DJ (2000) SOCS: physiological suppressors of cytokine signaling. J Cell Sci 113(Pt 16): 2813-2819.
51. Chen XP, Losman JA, Rothman P (2000) SOCS proteins, regulators of intracellular signaling. Immunity 13: 287-290.
52. Park Y, Shon SK, Kim A, Kim KI, Yang Y, et al. (2007) SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun 363: 361-367.
53. Hui KP, Lee SM, Cheung CY, Ng IH, Poon LL, et al. (2009) Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J Immunol 182: 1088-1098.
54. Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, et al. (2005) Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6: 135.
55. Gregorieff A, Pyronnet S, Sonenberg N, Veillette A (2000) Regulation of SOCS-1 expression by translational repression. J Biol Chem 275: 21596-21604.
56. Burgui I, Aragon T, Ortin J, Nieto A (2003) PABP1 and eIF4GI associate with influenza virus NS1 protein in viral mRNA translation initiation complexes. J Gen Virol 84: 3263-3274.
57. Aragon T, de la Luna S, Novoa I, Carrasco L, Ortin J, et al. (2000) Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. Mol Cell Biol 20: 6259-6268.
58. Asnaghi L, Bruno P, Priulla M, Nicolin A (2004) MTOR: a protein kinase switching between life and death. Pharmacol Res 50: 545-549.
59. Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M (2004) Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev. CD001169.
60. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193: 1626-1629.
61. von Itzstein M, Thomson R (2009) Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol. pp 111-154.
62. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
63. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
64. CDC (2009) Oseltamivir-Resistant Novel Influenza A (H1N1) Virus Infection in Two Immunosuppressed Patients. MMWR 893-896.
65. Hill AW, Guralnick RP, Wilson MJ, Habib F, Janies D (2009) Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Infect Genet Evol 9: 169-178.
66. Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, et al. (2009) Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 83: 3843-3851.